A monoclonal antibody directed against an epitope in the NH2-terminal region of native human plasminogen induces a modification of its functional properties

Fibrinolysis and Proteolysis

Volumn 11, Issue 3, 1997, Pages 155-163

  Mirshahi, Me ^a   Soria, J ^a   Lijnen, H R ^a   Fleury, V ^a   Bertrand, O ^a   Drouet, L ^a   Caen, J P ^a   Soria, C ^a  

^a Laboratoire DIFEMA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; EPITOPE MAPPING; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

EID: 0030696859     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80060-4     Document Type: Article

References (31)

1. Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-2342.
2. Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one mini-plasminogen (MW 38000) by elastase-catalyzed-specific limited proteolysis. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC eds. Progress in Chemical Fibrinolysis and Thrombolysis. New York: Raven Press, 1978; 3: 191-209.
3. Wallen P, Wiman B. Characterization of human plasminogen I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparation. Biochim. Biophys.Acta 1970; 221: 20-30.
4. Wallen P, Wiman B. Characterization of human plasminogen II. Separation and partial characterization of different molecular form of human plasminogen. Biochim Biophys Acta 1972; 257: 122-134.
5. Ponting CP, Holland SK, Cederholm-Williams SA, Marshall JM, Brown AJ, Spragon G, Blake CCF. The compact domain conformation of human Glu-plasminogen in solution. Biochem Biophys Acta 1992; 1159: 155-161.
6. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-amino-carboxylic acids. Biochim Biophys Acta 1975; 393: 55-65.
7. Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971; 138: 277-280.
8. Ploug M, Rönne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase-plasminogen activator-carboxy terminal processing and membrane anchoring by glycosyl-phosphatidyl inositol. J Biol Chem 1991; 266: 1926-1933.
9. Vassalli JD, Baccino D, Belin E. A cellular binding site for the Mr 55000 form of the human plasminogen activator urokinase. J Cell Biol 1985; 100: 86-92.
10. Nielsen LS, Kellarman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55000-60000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263: 2358-2363.
11. Rickli EE, Otavsky WI. Release of an N terminal peptide from human plasminogen during activation with urokinase. Biochim. Biophys Acta 1973; 295: 381-384.
12. Deutch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096.
13. Suter M, Butler JE, Peterman JH. The immunochemistry of sandwich Elisa-IH the stoechiometry and efficacy of the protein-avidin-biotin capture (PABC) system. Molecular Immunol 1989; 26: 221-230.
14. Kohler B, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specifity. Nature 1975; 256: 495-497.
15. Wolters G, Kuijpers L, Kacaki J, Schuurs A. Solid phase enzyme immunoassay for detection of hepatitis B surface antigen. J Clin Path 1976; 29: 873-879.
16. Mariani M, Camagna M, Traditi L, Seccamani E. A new enzymatic method to obtain high-yield F(ab)2 suitable for clinical use from mouse IgG1. Molecular Immunol 1991; 28: 69-77.
17. Adamson AW. The langmuir adsorption isotherm. In: Physical chemistry of surfaces. New York. John Viley & Sons Inc. 1990: 595-605.
18. Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 1991; 145: 229-240.
19. Vermylen C, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen polymerisation time (FPT test). Clin Chim Acta 1963; 8: 418-422.
20. Mirshahi Mc, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 1989; 74:1025-1030.
21. Mangel WF, Lin B, Ramakrishnan V. Characterization of an extremely large, ligand-induced conformational change in plasminogen. Science 1990; 248: 69-73.
22. Lijnen HR, Van Hoed B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase type plasminogen activator in a plasma milieu in vitro. Blood 1989; 73: 1864-1874.
23. Pannel R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effects. Blood 1986; 67: 1215-1223.
24. Marshall JM, Brown AJ, Ponting CP. Conformational studies of human plasminogen and plasminogen fragments: evidence for a new third conformation of plasminogen. Biochemistry 1994; 33: 3599-3606.
25. Miles LA, Levin EG, Plescis J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors and their modulation on human endothelial cells. Blood 1988; 72: 628-635.
26. Burtin P, Fondanèche MC. Receptor for plasmin on human carcinoma cells. J Nat Cancer Inst 1988; 80: 762-765.
27. Markus G, DePasquale JL, Wissler FC. Quantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen. J Biol Chem 1978; 253: 727-732.
28. Urano T, Takada Y, Takada A. Effects of N-terminal peptide of Glu-plasminogen on the activation of Glu-plasminogen and its conversion to Lys-plasminogen. Thrombos Res 1991; 61: 349-359.
29. Takada Y, Urano T, Takada A. Conformational change of plasminogen: effects of N-terminal peptides of Glu-plasminogen. Thrombos Res 1993; 70: 151-159
30. Marshall JM, Brown AJ, Ponting CP. Conformational studies of human plasminogen fragments: evidence for a novel third conformation of plasminogen. Biochem 1994; 33: 3599-3606.
31. Horrevoets AJG, Smilde AE, Frendenburgh JC; et al. The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the aminoterminal hinge region. J Biol Chem 1995; 270: 15770-15776.